{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:30:15Z","timestamp":1774971015745,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"DOI":"10.7759\/cureus.101059","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:59:50Z","timestamp":1767859190000},"source":"Crossref","is-referenced-by-count":1,"title":["Biologic Therapies: A Systematic Review of the Indications, Efficacy, Safety, and Outcomes in Ear, Nose, and Throat Diseases"],"prefix":"10.7759","author":[{"given":"Zainab","family":"Al Saloom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood","family":"Alawainati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahraa","family":"Abdeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israa","family":"Qadmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Mandeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"AlAani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12070-023-04309-9","article-title":"Biologics: the good, the bad and the future of ear, nose and throat","volume":"76","author":"Vincent V","year":"2024","unstructured":"Vincent V. Biologics: the good, the bad and the future of ear, nose and throat. Indian J Otolaryngol Head Neck Surg. 2024, 76:2176-81. 10.1007\/s12070-023-04309-9","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041079","article-title":"Advances in biologic therapies for allergic diseases: current trends, emerging agents, and future perspectives","volume":"14","author":"Alska E","year":"2025","unstructured":"Alska E, \u0141aszczych D, Napi\u00f3rkowska-Baran K, et al.. Advances in biologic therapies for allergic diseases: current trends, emerging agents, and future perspectives. J Clin Med. 2025, 14:1079. 10.3390\/jcm14041079","journal-title":"J Clin Med"},{"key":"ref3","article-title":"The evolving role of biologics in otorhinolaryngology: innovations, applications, and future perspectives","volume":"86","author":"Shrestha BL","year":"2024","unstructured":"Shrestha BL. The evolving role of biologics in otorhinolaryngology: innovations, applications, and future perspectives. Kathmandu Univ Med J. 2024, 86:231-4.","journal-title":"Kathmandu Univ Med J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S243053","article-title":"Dupilumab: clinical efficacy of blocking IL-4\/IL-13 signalling in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Kariyawasam HH","year":"2020","unstructured":"Kariyawasam HH, James LK, Gane SB. Dupilumab: clinical efficacy of blocking IL-4\/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Devel Ther. 2020, 14:1757-69. 10.2147\/DDDT.S243053","journal-title":"Drug Des Devel Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22994","article-title":"The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert P","year":"2022","unstructured":"Gevaert P, Han JK, Smith SG, et al.. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022, 12:1413-23. 10.1002\/alr.22994","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.09.041","article-title":"IgE directly affects eosinophil migration in chronic rhinosinusitis with nasal polyps through CCR3 and predicts the efficacy of omalizumab","volume":"153","author":"Yu J","year":"2024","unstructured":"Yu J, Yan B, Shen S, et al.. IgE directly affects eosinophil migration in chronic rhinosinusitis with nasal polyps through CCR3 and predicts the efficacy of omalizumab. J Allergy Clin Immunol. 2024, 153:447-60. 10.1016\/j.jaci.2023.09.041","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2022.103576","article-title":"Use of biologics for treatment of autoimmune inner ear disease","volume":"43","author":"Balouch B","year":"2022","unstructured":"Balouch B, Meehan R, Suresh A, et al.. Use of biologics for treatment of autoimmune inner ear disease. Am J Otolaryngol. 2022, 43:103576. 10.1016\/j.amjoto.2022.103576","journal-title":"Am J Otolaryngol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1945892418814768","article-title":"Biologic agents for the treatment of chronic rhinosinusitis with nasal polyps","volume":"33","author":"Kartush AG","year":"2019","unstructured":"Kartush AG, Schumacher JK, Shah R, Patadia MO. Biologic agents for the treatment of chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2019, 33:203-11. 10.1177\/1945892418814768","journal-title":"Am J Rhinol Allergy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin22.489","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens WJ","year":"2023","unstructured":"Fokkens WJ, Viskens AS, Backer V, et al.. EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023, 61:194-202. 10.4193\/Rhin22.489","journal-title":"Rhinology"},{"key":"ref10","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21(3)","author":"Barker TH","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, et al.. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023, 21(3):494-506.","journal-title":"JBI Evid Synth"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert C","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio RM, et al.. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016, 315:469-79. 10.1001\/jama.2015.19330","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert C","year":"2017","unstructured":"Bachert C, Sousa AR, Lund VJ, et al.. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017, 140:1024-31. 10.1016\/j.jaci.2017.05.044","journal-title":"J Allergy Clin Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS- 52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394(10209)","author":"Bachert C","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, et al.. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS- 52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019,  394(10209):1638-50. 10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin24.156","article-title":"Mepolizumab in CRSwNP\/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia","volume":"62","author":"Fujieda S","year":"2024","unstructured":"Fujieda S, Wang C, Yoshikawa M, et al.. Mepolizumab in CRSwNP\/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia. Rhinology. 2024, 62:576-89. 10.4193\/Rhin24.156","journal-title":"Rhinology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert P","year":"2022","unstructured":"Gevaert P, Saenz R, Corren J, et al.. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol. 2022, 149:957-65. 10.1016\/j.jaci.2021.07.045","journal-title":"J Allergy Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert P","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, et al.. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020, 146:595-605. 10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han JK","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, et al.. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021, 9:1141-53. 10.1016\/S2213-2600(21)00097-7","journal-title":"Lancet Respir Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23562","article-title":"Superior benefits of combining mepolizumab with sinus surgery compared to mepolizumab alone: results from a randomised 6-month trial","volume":"15","author":"Hom\u00f8e AS","year":"2025","unstructured":"Hom\u00f8e AS, Aan\u00e6s K, Tidemandsen JE, et al.. Superior benefits of combining mepolizumab with sinus surgery compared to mepolizumab alone: results from a randomised 6-month trial. Int Forum Allergy Rhinol. 2025, 15:724-33. 10.1002\/alr.23562","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.04.068","article-title":"Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study","volume":"8","author":"Okubo K","year":"2020","unstructured":"Okubo K, Okano M, Sato N, Tamaki Y, Suzuki H, Uddin A, Fogel R. Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study. J Allergy Clin Immunol Pract. 2020, 8:3130-40. 10.1016\/j.jaip.2020.04.068","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23471","article-title":"Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP","volume":"15","author":"Pelletier A","year":"2025","unstructured":"Pelletier A, Endam LM, Gonzalez E, Jannat S, Irani T, Desrosiers M. Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP. Int Forum Allergy Rhinol. 2025, 15:227-38. 10.1002\/alr.23471","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/all.16499","article-title":"Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: a meta-analysis of real-world evidence","volume":"80","author":"Cai S","year":"2025","unstructured":"Cai S, Xu S, Zhao Y, Zhang L. Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: a meta-analysis of real-world evidence. Allergy. 2025, 80:1256-70. 10.1111\/all.16499","journal-title":"Allergy"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104694","article-title":"Long-term real-world outcomes and insights of biologic therapies in chronic rhinosinusitis with nasal polyps","volume":"26","author":"Book R","year":"2025","unstructured":"Book R, Lazutkin A, Eliashar R. Long-term real-world outcomes and insights of biologic therapies in chronic rhinosinusitis with nasal polyps. Int J Mol Sci. 2025, 26:10.3390\/ijms26104694","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/01455613251362034","article-title":"Different response criteria and response rates for biologic therapy in patients with chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis","volume":"27","author":"Xu S","year":"2025","unstructured":"Xu S, Li Y, Pan X, Zhao Y, Wu D. Different response criteria and response rates for biologic therapy in patients with chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. Ear Nose Throat J. 2025, 27:1-14. 10.1177\/01455613251362034","journal-title":"Ear Nose Throat J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452470-biologic-therapies-a-systematic-review-of-the-indications-efficacy-safety-and-outcomes-in-ear-nose-and-throat-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:59:51Z","timestamp":1767859191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452470-biologic-therapies-a-systematic-review-of-the-indications-efficacy-safety-and-outcomes-in-ear-nose-and-throat-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.101059","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}